Tagged with

Pharma Faces Veronique Walsh, general manager of Bristol Myers Squibb for Belgium, the Netherlands, and Luxembourg (Benelux), recently spoke to PharmaBoardroom about her diverse career path, transitioning from medical doctor to pharmaceutical executive, and leading a large affiliate through the COVID-19 crisis.   Looking back over her slightly unusual career trajectory, Walsh,…

Merck Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and across the world. Moreover, the company is now increasingly at the forefront of digitalisation and innovation in its manufacturing and…

Korea Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big Pharma in their oncology projects, and the potential to become a pan-Asian venture in the future.   It is very…

Europe The European Medicines Agency (EMA), Europe’s regulatory body for medicines, has nominated Irish candidate Emer Cooke to as its new executive director at a crucial time for the agency as its powers and priorities shift in the wake of the COVID-19 crisis.   If Cooke accepts and gives an official…

Belgium In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in…

USA Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.   We have many programs currently in Phase III development. All these medicines are…

Italy Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector report and new studies on antibodies against Covid-19.   Menarini gains presence in US oncology market with acquisition of Stemline…

Coronavirus Against the backdrop of an unprecedented collaborative global push to develop a COVID-19 vaccine, pharma industry executives and patient advocacy representatives at the BIO 2020 digital conference discussed the progress made towards developing a HIV vaccine and what developers of potential COVID-19 treatments and vaccines can learn from it.  …

Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19.   Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…

China The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical tensions are affecting trade between China and India, and the country’s latest pharma billionaire.   China’s Sinopharm touts 100 percent antibody response for COVID-19 vaccine it’s already giving to workers https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving Tuesday, China’s state-run Sinopharm said (Chinese)…

USA Christopher Posner, US head for Danish medical dermatology specialist LEO Pharma, outlines how a mid-sized European company navigates the US market’s complex access and affordability issues, the innovations that the company is bringing to the US, and his leadership and HR philosophy.   My priority leading LEO Pharma Inc. in…

Korea Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another big-money deal for Takeda.   Since Takeda’s earthshattering announcement of its intended USD 62 billion acquisition of Shire – the…